Cargando…
A Novel Small Molecule Inhibitor of Hepatitis C Virus Entry
Small molecule inhibitors of hepatitis C virus (HCV) are being developed to complement or replace treatments with pegylated interferons and ribavirin, which have poor response rates and significant side effects. Resistance to these inhibitors emerges rapidly in the clinic, suggesting that successful...
Autores principales: | Baldick, Carl J., Wichroski, Michael J., Pendri, Annapurna, Walsh, Ann W., Fang, Jie, Mazzucco, Charles E., Pokornowski, Kevin A., Rose, Ronald E., Eggers, Betsy J., Hsu, Mayla, Zhai, Weixu, Zhai, Guangzhi, Gerritz, Samuel W., Poss, Michael A., Meanwell, Nicholas A., Cockett, Mark I., Tenney, Daniel J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936744/ https://www.ncbi.nlm.nih.gov/pubmed/20838466 http://dx.doi.org/10.1371/journal.ppat.1001086 |
Ejemplares similares
-
High-Throughput Screening and Rapid Inhibitor Triage Using an Infectious Chimeric Hepatitis C Virus
por: Wichroski, Michael J., et al.
Publicado: (2012) -
Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection
por: Balsitis, Scott, et al.
Publicado: (2018) -
Human Retroviral Host Restriction Factors APOBEC3G and APOBEC3F Localize to mRNA Processing Bodies
por: Wichroski, Michael J, et al.
Publicado: (2006) -
Topological vulnerability of power grids to disasters: Bounds, adversarial attacks and reinforcement
por: Deka, Deepjyoti, et al.
Publicado: (2018) -
DGKα/ζ inhibition lowers the TCR affinity threshold and potentiates antitumor immunity
por: Kureshi, Rakeeb, et al.
Publicado: (2023)